OrbiMed Raises $3B Across Two New Life Sciences Funds

· Health

OrbiMed, one of the largest life science investors in the world, has raised $3 billion across two new funds. Its 10th private equity fund in its flagship series gathered over $1.9 billion, while a second fund raised more than $1 billion specifically for Asia-focused investments. The raise comes as biotech financing conditions have been uneven, with public market investors anxious and private capital increasingly selective. Large dedicated healthcare funds are closely watched as a signal of where capital will flow next, particularly into early-stage drug development and regional markets. The size of the OrbiMed raise suggests institutional investors still see long-term opportunity in life sciences despite short-term volatility.

Why it matters：The scale of the raise signals institutional appetite for life sciences even in a volatile market, indicating where drug development capital may flow next globally.

Key points

  • The flagship private equity fund raised over $1.9 billion.
  • A second fund raised more than $1 billion for Asia.
  • It is OrbiMed's 10th fund in its flagship series.

Sources (original reporting)

More stories from this day